Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
Zoetis initiated with a Buy at Jefferies » 07:59
05/27/20
05/27
07:59
05/27/20
07:59
ZTS

Zoetis

$130.37 /

+0.29 (+0.22%)

Jefferies analyst David…

Jefferies analyst David Steinberg initiated coverage of Zoetis with a Buy rating and $152 price target. The "leading animal health company globally" has a track record of consistent and strong growth and he sees innovation and upcoming launches as keys to maintaining the company's above-market growth amid the "two megatrends" of pets becoming more integral to families and demand worldwide for animal protein, Steinberg tells investors.

ShowHide Related Items >><<
ZTS Zoetis
$130.37 /

+0.29 (+0.22%)

ZTS Zoetis
$130.37 /

+0.29 (+0.22%)

05/15/20 Citi
Elanco price target lowered to $27 from $35 at Citi
05/07/20 Barclays
Zoetis price target raised to $140 from $129 at Barclays
04/27/20 JPMorgan
JPMorgan cuts Zoetis and Elanco estimates after vet survey
04/23/20 Cantor Fitzgerald
Zoetis' long-term earnings potential underappreciated, says Cantor Fitzgerald
ZTS Zoetis
$130.37 /

+0.29 (+0.22%)

ZTS Zoetis
$130.37 /

+0.29 (+0.22%)

Tuesday
On The Fly
Fly Intel: After-Hours Movers » 18:24
05/26/20
05/26
18:24
05/26/20
18:24
STNE

StoneCo

$26.60 /

+2.14 (+8.75%)

, OOMA

Ooma

$13.47 /

+1.21 (+9.87%)

, TSCO

Tractor Supply

$111.19 /

-0.73 (-0.65%)

, HEI

Heico

$99.69 /

+5.78 (+6.15%)

, CHRS

Coherus Biosciences

$16.96 /

-0.16 (-0.93%)

, ESNT

Essent Group

$32.66 /

+2.55 (+8.47%)

, PTEN

Patterson-UTI

$3.89 /

+0.315 (+8.82%)

, JACK

Jack in the Box

$65.31 /

-1.27 (-1.91%)

, IDXX

Idexx Laboratories

$290.39 /

-4.18 (-1.42%)

, BMY

Bristol-Myers

$60.33 /

-0.45 (-0.74%)

, VSAT

ViaSat

$47.79 /

+5.59 (+13.25%)

, KEYS

Keysight Technologies

$103.49 /

+1.345 (+1.32%)

, SBLK

Star Bulk Carriers

$5.29 /

+0.18 (+3.52%)

, RPAY

Repay Holdings

$21.97 /

-1.05 (-4.56%)

, FVRR

Fiverr

$62.10 /

+2.45 (+4.11%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
VSAT ViaSat
$47.79 /

+5.59 (+13.25%)

TSCO Tractor Supply
$111.19 /

-0.73 (-0.65%)

STNE StoneCo
$26.60 /

+2.14 (+8.75%)

SBLK Star Bulk Carriers
$5.29 /

+0.18 (+3.52%)

RPAY Repay Holdings
$21.97 /

-1.05 (-4.56%)

PTEN Patterson-UTI
$3.89 /

+0.315 (+8.82%)

OOMA Ooma
$13.47 /

+1.21 (+9.87%)

KEYS Keysight Technologies
$103.49 /

+1.345 (+1.32%)

JACK Jack in the Box
$65.31 /

-1.27 (-1.91%)

IDXX Idexx Laboratories
$290.39 /

-4.18 (-1.42%)

HEI Heico
$99.69 /

+5.78 (+6.15%)

FVRR Fiverr
$62.10 /

+2.45 (+4.11%)

ESNT Essent Group
$32.66 /

+2.55 (+8.47%)

CHRS Coherus Biosciences
$16.96 /

-0.16 (-0.93%)

BMY Bristol-Myers
$60.33 /

-0.45 (-0.74%)

STNE StoneCo
$26.60 /

+2.14 (+8.75%)

05/19/20 Citi
StoneCo price target raised to $30 from $28 at Citi
03/31/20 Citi
StoneCo price target lowered to $28 from $50 at Citi
03/27/20 HSBC
StoneCo upgraded to Hold from Reduce at HSBC
03/03/20 Cantor Fitzgerald
StoneCo price target raised to $49 from $40 at Cantor Fitzgerald
OOMA Ooma
$13.47 /

+1.21 (+9.87%)

03/16/20
Fly Intel: Top five analyst initiations
03/16/20 Alliance Global Partners
Ooma initiated with a Buy at Alliance Global Partners
09/30/19 BofA
BofA/Merrill downgrades Ooma to Underperform, sees re-acceleration as unlikely
09/30/19 BofA
Ooma downgraded to Underperform from Neutral at BofA/Merrill
TSCO Tractor Supply
$111.19 /

-0.73 (-0.65%)

05/19/20 Northcoast
Tractor Supply downgraded to Neutral from Buy at Northcoast
04/23/20 Baird
Tractor Supply price target raised to $115 from $105 at Baird
04/23/20 Baird
Tractor Supply Q2 off to 'strong start,' says Baird
04/15/20 Wedbush
Tractor Supply downgraded to Neutral at Wedbush as optimism priced in
HEI Heico
$99.69 /

+5.78 (+6.15%)

05/18/20 Canaccord
Heico downgraded to Hold at Canaccord
05/18/20 Canaccord
Heico downgraded to Hold from Buy at Canaccord
03/31/20 Jefferies
Heico downgraded to Hold from Buy at Jefferies
03/30/20 Vertical Research
Heico downgraded to Hold from Buy at Vertical Research
CHRS Coherus Biosciences
$16.96 /

-0.16 (-0.93%)

04/17/20 SunTrust
Coherus Biosciences initiated with a Buy at SunTrust
04/17/20 SunTrust
Coherus Biosciences initiated with a Buy at SunTrust
04/13/20 Citi
Sharp drop in chemo use negative for Amgen and Coherus, says Citi
02/05/20 Mizuho
Mizuho sees 'immaterial' impact on Coherus shares from BLA withdrawal
ESNT Essent Group
$32.66 /

+2.55 (+8.47%)

05/12/20 Deutsche Bank
Essent Group price target lowered to $47 from $58 at Deutsche Bank
03/26/20 MKM Partners
MKM Partners sees Mortgage Insurers as attractively valued
03/26/20 RBC Capital
Essent Group price target lowered to $36 from $62 at RBC Capital
03/11/20 MKM Partners
Essent Group upgraded to Buy from Neutral at MKM Partners
PTEN Patterson-UTI
$3.89 /

+0.315 (+8.82%)

04/27/20 Gabelli
Patterson-UTI downgraded to Hold from Buy at Gabelli
04/14/20 Cowen
Patterson-UTI downgraded to Market Perform at Cowen
04/14/20 Cowen
Patterson-UTI downgraded to Market Perform from Outperform at Cowen
04/05/20 Bernstein
Patterson-UTI upgraded to Market Perform from Underperform at Bernstein
JACK Jack in the Box
$65.31 /

-1.27 (-1.91%)

05/26/20 Goldman Sachs
Jack in the Box upgraded to Neutral from Sell at Goldman Sachs
05/26/20 Goldman Sachs
Jack in the Box upgraded to Neutral from Sell at Goldman Sachs
05/15/20 SunTrust
Jack in the Box price target raised to $86 from $79 at SunTrust
05/15/20 Cowen
Jack in the Box price target raised to $68 from $42 at Cowen
IDXX Idexx Laboratories
$290.39 /

-4.18 (-1.42%)

04/27/20 Cleveland Research
Idexx Laboratories checks on placements look soft, says Cleveland Research
03/13/20 Cleveland Research
Demand for Zoetis' Simparica Trio 'robust,' says Cleveland Research
12/19/19 BofA
Elanco upgraded to Buy from Neutral at BofA/Merrill
10/24/19 William Blair
Idexx Laboratories should be bought on any weakness, says William Blair
BMY Bristol-Myers
$60.33 /

-0.45 (-0.74%)

05/13/20 Stifel
Bluebird's ide-cel remains approvable despite FDA's 'strict stance,' says Stifel
05/13/20 Piper Sandler
Bluebird should be able to easily address RTF issues, says Piper Sandler
05/12/20 Oppenheimer
Bluebird Bio price target lowered to $111 from $122 at Oppenheimer
04/20/20 Piper Sandler
Exelixis combo approval would increase kidney cancer use, says Piper Sandler
VSAT ViaSat
$47.79 /

+5.59 (+13.25%)

05/20/20 William Blair
ViaSat defense contract renewal positive for shares, says William Blair
04/20/20 Barclays
Barclays upgrades ViaSat to Equal Weight on more balanced risk/reward
04/20/20 Barclays
ViaSat upgraded to Equal Weight from Underweight at Barclays
03/13/20 William Blair
Delta dual sourcing Wi-Fi potentially positive for ViaSat, says William Blair
KEYS Keysight Technologies
$103.49 /

+1.345 (+1.32%)

04/14/20 JPMorgan
Keysight Technologies initiated with a Neutral at JPMorgan
03/18/20 Stifel
Keysight demand should remain healthy post-crisis, says Stifel
03/04/20 Citi
Keysight 'best and most agnostic way' to play 5G, says Citi
02/25/20 Deutsche Bank
Keysight Technologies price target raised to $130 from $125 at Deutsche Bank
SBLK Star Bulk Carriers
$5.29 /

+0.18 (+3.52%)

03/09/20 DNB Markets
Star Bulk Carriers downgraded to Hold from Buy at DNB Markets
02/20/20 Fearnley
Star Bulk Carriers upgraded to Buy from Hold at Fearnley
01/27/20 Fearnley
Star Bulk Carriers downgraded to Hold from Buy at Fearnley
11/13/19 Pareto
Star Bulk Carriers downgraded to Hold from Buy at Pareto
RPAY Repay Holdings
$21.97 /

-1.05 (-4.56%)

05/19/20 BTIG
Repay Holdings price target raised to $25 from $20 at BTIG
04/17/20
Fly Intel: Top five analyst initiations
04/17/20 DA Davidson
Repay Holdings initiated with a Buy at DA Davidson
03/17/20 Canaccord
Repay Holdings outlook could be helped by current environment, says Canaccord
FVRR Fiverr
$62.10 /

+2.45 (+4.11%)

05/08/20 JPMorgan
Fiverr price target raised to $54 from $37 at JPMorgan
02/21/20
Fiverr management to meet with Oppenheimer
02/20/20
Fly Intel: Top five analyst upgrades
02/20/20 JPMorgan
Fiverr upgraded to Overweight with $37 price target at JPMorgan
VSAT ViaSat
$47.79 /

+5.59 (+13.25%)

TSCO Tractor Supply
$111.19 /

-0.73 (-0.65%)

STNE StoneCo
$26.60 /

+2.14 (+8.75%)

SBLK Star Bulk Carriers
$5.29 /

+0.18 (+3.52%)

PTEN Patterson-UTI
$3.89 /

+0.315 (+8.82%)

OOMA Ooma
$13.47 /

+1.21 (+9.87%)

KEYS Keysight Technologies
$103.49 /

+1.345 (+1.32%)

JACK Jack in the Box
$65.31 /

-1.27 (-1.91%)

IDXX Idexx Laboratories
$290.39 /

-4.18 (-1.42%)

HEI Heico
$99.69 /

+5.78 (+6.15%)

FVRR Fiverr
$62.10 /

+2.45 (+4.11%)

ESNT Essent Group
$32.66 /

+2.55 (+8.47%)

CHRS Coherus Biosciences
$16.96 /

-0.16 (-0.93%)

BMY Bristol-Myers
$60.33 /

-0.45 (-0.74%)

  • 29
    May
  • 29
    May
PTEN Patterson-UTI
$3.89 /

+0.315 (+8.82%)

BMY Bristol-Myers
$60.33 /

-0.45 (-0.74%)

TSCO Tractor Supply
$111.19 /

-0.73 (-0.65%)

PTEN Patterson-UTI
$3.89 /

+0.315 (+8.82%)

JACK Jack in the Box
$65.31 /

-1.27 (-1.91%)

HEI Heico
$99.69 /

+5.78 (+6.15%)

BMY Bristol-Myers
$60.33 /

-0.45 (-0.74%)

VSAT ViaSat
$47.79 /

+5.59 (+13.25%)

TSCO Tractor Supply
$111.19 /

-0.73 (-0.65%)

STNE StoneCo
$26.60 /

+2.14 (+8.75%)

RPAY Repay Holdings
$21.97 /

-1.05 (-4.56%)

KEYS Keysight Technologies
$103.49 /

+1.345 (+1.32%)

HEI Heico
$99.69 /

+5.78 (+6.15%)

FVRR Fiverr
$62.10 /

+2.45 (+4.11%)

BMY Bristol-Myers
$60.33 /

-0.45 (-0.74%)

Hot Stocks
Idexx Laboratories sees 'meaningful improvement in U.S. clinical visit trends' » 17:02
05/26/20
05/26
17:02
05/26/20
17:02
IDXX

Idexx Laboratories

$290.39 /

-4.18 (-1.42%)

Idexx Laboratories…

Idexx Laboratories provided an update on U.S. Companion Animal Market Trends through Friday, May 22nd. "We are monitoring the impact of the COVID-19 pandemic on U.S. companion animal practice visit trends, including the effect of stay-at-home and social distancing policies to prevent the spread of COVID-19, as well as the related prioritization of sick and emergency testing at veterinary clinics. With an additional four weeks of activity since our last update, we continue to see meaningful improvement in U.S. clinical visit trends across major regions, with overall U.S. clinical visits, non-wellness visits and wellness visits surpassing prior year levels in the most recent week ended May 22nd."

ShowHide Related Items >><<
IDXX Idexx Laboratories
$290.39 /

-4.18 (-1.42%)

IDXX Idexx Laboratories
$290.39 /

-4.18 (-1.42%)

04/27/20 Cleveland Research
Idexx Laboratories checks on placements look soft, says Cleveland Research
03/13/20 Cleveland Research
Demand for Zoetis' Simparica Trio 'robust,' says Cleveland Research
12/19/19 BofA
Elanco upgraded to Buy from Neutral at BofA/Merrill
10/24/19 William Blair
Idexx Laboratories should be bought on any weakness, says William Blair
IDXX Idexx Laboratories
$290.39 /

-4.18 (-1.42%)

Over a week ago
Hot Stocks
Kindred Biosciences enters COVID-19 vaccine manufacturing agremeent with Vaxart » 08:00
05/20/20
05/20
08:00
05/20/20
08:00
KIN

Kindred Biosciences

$4.55 /

-0.45 (-9.00%)

, VXRT

Vaxart

$3.06 /

+0.2 (+6.99%)

Kindred Biosciences (KIN)…

Kindred Biosciences (KIN) has entered into an agreement with Vaxart (VXRT) for the manufacture of Vaxart's oral vaccine candidate for COVID-19. KindredBio will provide manufacturing services from its biological development and cGMP manufacturing facility in Burlingame, CA. There, KindredBio will produce the candidate vaccine bulk drug substance under Good Manufacturing Practices, and provide it to Vaxart to be formulated into a vaccine tablet to be taken by mouth instead of by needle injection. KindredBio will manufacture the vaccine for clinical trials beginning in the second half of 2020.

ShowHide Related Items >><<
VXRT Vaxart
$3.06 /

+0.2 (+6.99%)

KIN Kindred Biosciences
$4.55 /

-0.45 (-9.00%)

KIN Kindred Biosciences
$4.55 /

-0.45 (-9.00%)

03/17/20 Guggenheim
Kindred Biosciences downgraded to Neutral from Buy at Guggenheim
07/16/19 B. Riley FBR
Kindred Biosciences downgraded to Neutral from Buy at B. Riley FBR
07/16/19 B. Riley FBR
Kindred Biosciences downgraded to Neutral from Buy at B. Riley FBR
06/11/19 Barclays
Kindred Biosciences initiated with an Overweight at Barclays
VXRT Vaxart
$3.06 /

+0.2 (+6.99%)

04/30/20 H.C. Wainwright
Vaxart price target raised to $7 from $3 at H.C. Wainwright
08/15/19 Brookline
Vaxart initiated with a Buy at Brookline
06/27/19 H.C. Wainwright
Vaxart initiated with a Buy at H.C. Wainwright
KIN Kindred Biosciences
$4.55 /

-0.45 (-9.00%)

VXRT Vaxart
$3.06 /

+0.2 (+6.99%)

KIN Kindred Biosciences
$4.55 /

-0.45 (-9.00%)

VXRT Vaxart
$3.06 /

+0.2 (+6.99%)

Recommendations
Elanco price target lowered to $27 from $35 at Citi » 06:27
05/15/20
05/15
06:27
05/15/20
06:27
ELAN

Elanco

$19.34 /

+0.05 (+0.26%)

, ZTS

Zoetis

$125.75 /

+2.55 (+2.07%)

Citi analyst Navann Ty…

Citi analyst Navann Ty lowered the firm's price target on Elanco Animal Health (ELAN) to $27 from $35 and keeps a Buy rating on the shares. The company reported a Q1 miss on COVID-related inventory reduction, Ty tells investors in a research note. The analyst reduced estimates mainly due to the "unexpected" inventory destocking and the related mix impact on operating margins. The revamping its distribution channels is a "valid strategy" following the consolidation of distributors in January, although the revamp along with COVID-19 will delay Elanco's margin expansion story and the expected partial catch up with Zoetis (ZTS), says Ty.

ShowHide Related Items >><<
ZTS Zoetis
$125.75 /

+2.55 (+2.07%)

ELAN Elanco
$19.34 /

+0.05 (+0.26%)

ELAN Elanco
$19.34 /

+0.05 (+0.26%)

04/27/20 JPMorgan
JPMorgan cuts Zoetis and Elanco estimates after vet survey
04/02/20 Morgan Stanley
Elanco downgraded to Equal Weight on earnings risk at Morgan Stanley
04/02/20 Morgan Stanley
Elanco downgraded to Equal Weight from Overweight at Morgan Stanley
01/10/20 Raymond James
Elanco well positioned in growing animal health market, says Raymond James
ZTS Zoetis
$125.75 /

+2.55 (+2.07%)

05/07/20 Barclays
Zoetis price target raised to $140 from $129 at Barclays
04/23/20 Cantor Fitzgerald
Zoetis' long-term earnings potential underappreciated, says Cantor Fitzgerald
03/23/20 SunTrust
SunTrust lowers price targets among Pharmaceuticals due to COVID-19
ZTS Zoetis
$125.75 /

+2.55 (+2.07%)

ELAN Elanco
$19.34 /

+0.05 (+0.26%)

ZTS Zoetis
$125.75 /

+2.55 (+2.07%)

ELAN Elanco
$19.34 /

+0.05 (+0.26%)

ELAN Elanco
$19.34 /

+0.05 (+0.26%)

Syndicate
PetIQ announces proposed convertible senior notes offering to fund Capstar deal » 08:50
05/14/20
05/14
08:50
05/14/20
08:50
PETQ

PetIQ

$27.13 /

-1.44 (-5.04%)

, ELAN

Elanco

$19.29 /

-0.69 (-3.45%)

PetIQ (PETQ) announced…

PetIQ (PETQ) announced its intention to offer, subject to market and other conditions, $125,000,000 aggregate principal amount of convertible senior notes due 2026 in a private offering. PetIQ also expects to grant the initial purchasers of the notes a 30-day option to purchase up to an additional $18,750,000 principal amount of notes. The notes will be senior, unsecured obligations of PetIQ, will accrue interest payable semi-annually in arrears and will mature on June 1, 2026, unless earlier repurchased, redeemed or converted. Noteholders will have the right to convert their notes in certain circumstances and during specified periods. PetIQ will settle conversions by paying or delivering, as applicable, cash, shares of its Class A common stock or a combination of cash and shares of its Class A common stock, at PetIQ's election. The notes will be redeemable, in whole or in part, for cash at PetIQ's option at any time, and from time to time, on or after June 1, 2023 and on or before the 40th scheduled trading day immediately before the maturity date, but only if the last reported sale price per share of PetIQ's Class A common stock exceeds 130% of the conversion price for a specified period of time. The redemption price will be equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. The interest rate, initial conversion rate and other terms of the notes will be determined at the pricing of the offering. PetIQ intends to loan the proceeds of the offering, after deducting the initial purchasers' discounts and commissions and the cost of entering into the capped call transactions described below, to PetIQ Holdings, LLC. PetIQ intends to cause Holdco to use the remaining proceeds to pay its offering expenses, to fund PetIQ's previously announced acquisition of the Capstar portfolio from Elanco Animal Health (ELAN) and related fees and expenses, and for working capital and other general corporate purposes. In connection with the pricing of the notes, PetIQ expects to enter into privately negotiated capped call transactions with one or more dealers.

ShowHide Related Items >><<
PETQ PetIQ
$27.13 /

-1.44 (-5.04%)

ELAN Elanco
$19.29 /

-0.69 (-3.45%)

PETQ PetIQ
$27.13 /

-1.44 (-5.04%)

05/08/20 SunTrust
PetIQ price target raised to $35 from $30 at SunTrust
05/23/19 Guggenheim
PetIQ initiated with a Buy at Guggenheim
ELAN Elanco
$19.29 /

-0.69 (-3.45%)

04/27/20 JPMorgan
JPMorgan cuts Zoetis and Elanco estimates after vet survey
04/02/20 Morgan Stanley
Elanco downgraded to Equal Weight on earnings risk at Morgan Stanley
04/02/20 Morgan Stanley
Elanco downgraded to Equal Weight from Overweight at Morgan Stanley
01/10/20 Raymond James
Elanco well positioned in growing animal health market, says Raymond James
PETQ PetIQ
$27.13 /

-1.44 (-5.04%)

ELAN Elanco
$19.29 /

-0.69 (-3.45%)

ELAN Elanco
$19.29 /

-0.69 (-3.45%)

ELAN Elanco
$19.29 /

-0.69 (-3.45%)

Earnings
Kindred Biosciences reports Q1 EPS (58c), consensus (43c) » 16:41
05/07/20
05/07
16:41
05/07/20
16:41
KIN

Kindred Biosciences

$4.56 /

-0.215 (-4.50%)

Reports Q1 revenue $603K,…

Reports Q1 revenue $603K, consensus $1.59M. "We are very pleased with the recent close of the $43M Mirataz transaction. We look forward to continuing to build value in our promising pipeline," said CEO, Richard Chin. "With the positive results from the IL-4/13 SINK pilot study we now have eight positive pilot studies in a row, which is a remarkable achievement, and speaks to the quality of our development capabilities."

ShowHide Related Items >><<
KIN Kindred Biosciences
$4.56 /

-0.215 (-4.50%)

03/17/20 Guggenheim
Kindred Biosciences downgraded to Neutral from Buy at Guggenheim
07/16/19 B. Riley FBR
Kindred Biosciences downgraded to Neutral from Buy at B. Riley FBR
07/16/19 B. Riley FBR
Kindred Biosciences downgraded to Neutral from Buy at B. Riley FBR
06/11/19 Barclays
Kindred Biosciences initiated with an Overweight at Barclays
On The Fly
Fly Intel: Pre-market Movers » 09:08
05/07/20
05/07
09:08
05/07/20
09:08
MRNA

Moderna

$48.94 /

-0.4 (-0.81%)

, EVLO

Evelo Biosciences

$4.83 /

+0.025 (+0.52%)

, BMY

Bristol-Myers

$61.14 /

-0.21 (-0.34%)

, RTX

Raytheon Technologies

$57.92 /

-1.08 (-1.83%)

, BUD

AB InBev

$42.65 /

+1.12 (+2.70%)

, HLT

Hilton

$70.84 /

-0.92 (-1.28%)

, VIAC

ViacomCBS

$14.89 /

-0.37 (-2.42%)

, COMM

CommScope

$10.19 /

+0.04 (+0.39%)

, VG

Vonage

$8.44 /

+0.14 (+1.69%)

, ELAN

Elanco

$23.01 /

-1.14 (-4.72%)

, JBLU

JetBlue

$8.00 /

-0.28 (-3.38%)

, SAVE

Spirit Airlines

$11.55 /

-0.765 (-6.21%)

, ETSY

Etsy

$78.60 /

+5.82 (+8.00%)

, EYE

National Vision

$23.96 /

-0.46 (-1.88%)

, VAPO

Vapotherm

$30.00 /

+7.59 (+33.87%)

Check out this morning's…

Open Full Text

ShowHide Related Items >><<
MRNA Moderna
$48.94 /

-0.4 (-0.81%)

05/01/20 Piper Sandler
Moderna 'dramatically' expanded COVID vaccine production, says Piper Sandler
04/30/20
Fly Intel: Top five analyst initiations
04/29/20 BMO Capital
BMO starts Moderna with Outperform, $83 target on vaccine potential
04/29/20 BMO Capital
Moderna initiated with an Outperform at BMO Capital
EVLO Evelo Biosciences
$4.83 /

+0.025 (+0.52%)

BMY Bristol-Myers
$61.14 /

-0.21 (-0.34%)

04/20/20 Piper Sandler
Exelixis combo approval would increase kidney cancer use, says Piper Sandler
04/02/20
Fly Intel: Top five analyst upgrades
04/02/20 Morgan Stanley
Bristol-Myers upgraded to Overweight after pullback at Morgan Stanley
04/02/20 Morgan Stanley
Bristol-Myers upgraded to Overweight from Equal Weight at Morgan Stanley
RTX Raytheon Technologies
$57.92 /

-1.08 (-1.83%)

04/20/20 Credit Suisse
Raytheon Technologies price target lowered to $81 from $101.45 at Credit Suisse
04/15/20 JPMorgan
Raytheon Technologies downgraded to Neutral upon assumption at JPMorgan
04/15/20 JPMorgan
Raytheon Technologies downgraded to Neutral from Overweight at JPMorgan
04/15/20 Goldman Sachs
Raytheon Technologies reinstated with a Buy at Goldman Sachs
BUD AB InBev
$42.65 /

+1.12 (+2.70%)

04/20/20 Morgan Stanley
AB InBev downgraded to Equal Weight from Overweight at Morgan Stanley
04/13/20 Evercore ISI
Beer production not resuming in Mexico, says Evercore ISI
04/09/20
Fly Intel: Top five analyst upgrades
04/09/20 HSBC
AB InBev upgraded to Hold from Reduce at HSBC
HLT Hilton
$70.84 /

-0.92 (-1.28%)

04/22/20 BofA
Choice Hotels upgraded to Neutral from Underperform at Bofa
04/14/20 Barclays
Investors should start preparing to buy lodging stocks, says Barclays
04/09/20 Wolfe Research
Hilton downgraded to Peer Perform from Outperform at Wolfe Research
04/09/20 Argus
Hilton downgraded to Hold from Buy at Argus
VIAC ViacomCBS
$14.89 /

-0.37 (-2.42%)

04/27/20 RBC Capital
ViacomCBS initiated with a Sector Perform at RBC Capital
04/23/20 Evercore ISI
ViacomCBS downgraded to In Line from Outperform at Evercore ISI
04/15/20 Citi
ViacomCBS price target lowered to $20 from $51 at Citi
04/13/20 Deutsche Bank
ViacomCBS shares have 90% upside as recovery begins, says Deutsche Bank
COMM CommScope
$10.19 /

+0.04 (+0.39%)

05/05/20
Fly Intel: Top five analyst initiations
05/05/20 Loop Capital
CommScope initiated with a Hold at Loop Capital
05/05/20 Loop Capital
CommScope initiated with a Hold at Loop Capital
04/20/20 JPMorgan
JPMorgan downgrades CommScope on limited EBITDA growth potential
VG Vonage
$8.44 /

+0.14 (+1.69%)

04/15/20 Citi
Vonage price target raised to $10 from $7 at Citi
03/25/20 Morgan Stanley
Morgan Stanley says Vonage discount too steep, upgrades to Overweight
03/25/20 Morgan Stanley
Vonage upgraded to Overweight from Equal Weight at Morgan Stanley
03/25/20 Morgan Stanley
Vonage upgraded to Overweight from Equal Weight at Morgan Stanley
ELAN Elanco
$23.01 /

-1.14 (-4.72%)

04/27/20 JPMorgan
JPMorgan cuts Zoetis and Elanco estimates after vet survey
04/02/20 Morgan Stanley
Elanco downgraded to Equal Weight on earnings risk at Morgan Stanley
04/02/20 Morgan Stanley
Elanco downgraded to Equal Weight from Overweight at Morgan Stanley
01/10/20 Raymond James
Elanco well positioned in growing animal health market, says Raymond James
JBLU JetBlue
$8.00 /

-0.28 (-3.38%)

05/04/20 Barclays
Barclays downgrades U.S. Airlines sector along with American and Delta
05/04/20 Barclays
JetBlue price target lowered to $11 from $16 at Barclays
04/21/20
Fly Intel: Top five analyst downgrades
04/21/20 Susquehanna
JetBlue downgraded to Neutral at Susquehanna
SAVE Spirit Airlines
$11.55 /

-0.765 (-6.21%)

05/07/20
Spirit Airlines: Pandemic has had 'profound' impact on company, industry
05/04/20 Barclays
Spirit Airlines price target lowered to $20 from $25 at Barclays
04/21/20 Deutsche Bank
Spirit Airlines price target lowered to $24 from $26 at Deutsche Bank
ETSY Etsy
$78.60 /

+5.82 (+8.00%)

05/07/20 Canaccord
Etsy price target raised to $85 from $70 at Canaccord
05/07/20 Wedbush
Etsy price target raised to $88 from $75 at Wedbush
05/07/20 SunTrust
Etsy price target raised to $88 from $53 at SunTrust
05/07/20 Deutsche Bank
Etsy price target raised to $86 from $65 at Deutsche Bank
EYE National Vision
$23.96 /

-0.46 (-1.88%)

04/17/20 Barclays
National Vision price target lowered to $28 from $44 at Barclays
03/24/20 Citi
National Vision price target lowered to $34 from $44 at Citi
03/23/20 Wells Fargo
National Vision price target lowered to $22 from $42 at Wells Fargo
02/03/20 BMO Capital
National Vision initiated with a Market Perform at BMO Capital
VAPO Vapotherm
$30.00 /

+7.59 (+33.87%)

05/06/20 Canaccord
Vapotherm price target raised to $30 from $20 at Canaccord
04/14/20 Canaccord
Vapotherm price target raised to $20 from $14 at Canaccord
03/05/20 Canaccord
Vapotherm remains top 2020 turnaround pick, says Canaccord
06/05/19 Canaccord
Vapotherm remains a top small-cap pick, says Canaccord
  • 08
    May
  • 07
    May
Hot Stocks
OPTI Medical receives FDA EUA for OPTI SARS-CoV-2 RNA PCR test kit » 07:38
05/07/20
05/07
07:38
05/07/20
07:38
IDXX

Idexx Laboratories

$283.47 /

+1.45 (+0.51%)

OPTI Medical Systems, a…

OPTI Medical Systems, a subsidiary of IDEXX Laboratories, announced that the United States FDA has granted Emergency Use Authorization for the OPTI SARS-CoV-2 RT-PCR laboratory test kit for the detection of SARS-CoV-2, the virus that causes COVID-19. This announcement follows earlier validation of the test by the Institut Pasteur of France.

ShowHide Related Items >><<
IDXX Idexx Laboratories
$283.47 /

+1.45 (+0.51%)

04/27/20 Cleveland Research
Idexx Laboratories checks on placements look soft, says Cleveland Research
03/13/20 Cleveland Research
Demand for Zoetis' Simparica Trio 'robust,' says Cleveland Research
12/19/19 BofA
Elanco upgraded to Buy from Neutral at BofA/Merrill
10/24/19 William Blair
Idexx Laboratories should be bought on any weakness, says William Blair
Recommendations
Zoetis price target raised to $140 from $129 at Barclays » 06:54
05/07/20
05/07
06:54
05/07/20
06:54
ZTS

Zoetis

$125.65 /

-5.62 (-4.28%)

Barclays analyst Balaji…

Barclays analyst Balaji Prasad raised the firm's price target on Zoetis to $140 from $129 and keeps an Overweight rating on the shares. The analyst believes the company's guidance cut is reasonable in a period of limited near-term visibility. Prasad maintains a strong outlook for 2021 and expects the focus to shift to 2021 earnings.

ShowHide Related Items >><<
ZTS Zoetis
$125.65 /

-5.62 (-4.28%)

04/27/20 JPMorgan
JPMorgan cuts Zoetis and Elanco estimates after vet survey
04/23/20 Cantor Fitzgerald
Zoetis' long-term earnings potential underappreciated, says Cantor Fitzgerald
03/23/20 SunTrust
SunTrust lowers price targets among Pharmaceuticals due to COVID-19
03/13/20 Cleveland Research
Demand for Zoetis' Simparica Trio 'robust,' says Cleveland Research

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.